Edition:
United Kingdom

Akers Biosciences Inc (AKER.OQ)

AKER.OQ on NASDAQ Stock Exchange Capital Market

0.25USD
24 Sep 2018
Change (% chg)

-- (--)
Prev Close
$0.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
486,502
52-wk High
$1.82
52-wk Low
$0.12

Select another date:

Wed, May 16 2018

BRIEF-Akers Biosciences Files Non Timely 10-Q - SEC Filing

* AKERS BIOSCIENCES INC FILES NON TIMELY 10-Q - SEC FILING Source text: (https://bit.ly/2k6a2jr) Further company coverage:

BRIEF-Akers Biosciences Says Terminated Raymond Akers Positions As Executive Chairman

* SAYS TERMINATED RAYMOND AKERS POSITIONS AS EXECUTIVE CHAIRMAN, CHIEF SCIENTIFIC DIRECTOR AND SECRETARY OF COMPANY

BRIEF-Akers Biosciences Says Appointed Richard Carlyle Tarbox III As Interim Non-Executive Chairman

* AKERS BIOSCIENCES - BOARD TERMINATED RAYMOND AKERS FROM POSITION AS EXECUTIVE CHAIRMAN OF BOARD, CHIEF SCIENTIFIC DIRECTOR AND SECRETARY OF COMPANY

BRIEF-Akers Biosciences Expands Outsourced U.S. Distribution Capabilities For Heparin PF4 Rapid Test

* AKERS BIOSCIENCES EXPANDS OUTSOURCED US DISTRIBUTION CAPABILITIES FOR HEPARIN PF4 RAPID TEST

BRIEF-Akers Biosciences Reports Earnings For Fiscal Year 2017

* AKERS BIOSCIENCES REPORTS EARNINGS FOR FISCAL YEAR 2017 Source text for Eikon: Further company coverage:

BRIEF-Akers Biosciences Signs Distribution Agreement With Diagnostica Stago

* AKERS BIOSCIENCES SIGNS US DISTRIBUTION AGREEMENT WITH DIAGNOSTICA STAGO

BRIEF-Akers Biosciences Announces Distribution Agreement With Diagnostica Stago​

* ‍ENTERED INTO 3-YEAR DISTRIBUTION AGREEMENT WITH DIAGNOSTICA STAGO FOR SALE OF CO'S RAPID TEST FOR HEPARIN-INDUCED THROMBOCYTOPENIA ACROSS US​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Select another date: